Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Elrig 2018: Drug discovery using small and large molecules

The Drug Target Review team are at Elrig Drug Discovery 2018 in the London ExCel…

Elrig 2018

The Drug Target Review team are attending Elrig 2018 today at the London ExCel. With the event hosting 50 talks over the course of two days, it is the perfect place to be up-to-date with today’s technologies and research.

The initial talk of the day we attended was based on Bicycle Therapeutics in cancer therapy. Dr Gemma Mudd spoke around highly potent and selective tumour targeting bicyclic peptides as a novel approach Ron cancer therapeutics. She spoke of the identification and optimisation of the high affinity bicycle targeting EphA2, and it took only 40 analogues from the initial compound, BCY6009, to the final compound BCY6099. 

Dr Mudd explained how around 70 conjugate toxins were screened before the optimal one was chosen and bound to the compound. The final compound BT5528 maintained efficacy in CDX models. The research team found a significant regression of the tumour after 21 days, at the dose of 3 milligrams per kilogram per week. This compound is now in preclinical trials.

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

The talk spoke of novel drug modality and multiple applications of Bicycle molecules. Dr Mudd spoke of the profound efficacy of these compounds, and finished with a question and answer session.

The Drug Target Review team hope to meet more researchers and learn more about the new therapeutics currently in process over the course of the event.